Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sound waves zap breast lumps: no scalpel needed?

NCT ID NCT03044054

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a device that uses high-intensity focused ultrasound (HIFU) to treat breast fibroadenomas—noncancerous lumps. 113 women received the treatment, and researchers measured pain, anxiety, and lump size. The goal was to see if HIFU can safely shrink these lumps without surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
high-intensity focused ultrasound (HIFU) device
What this could lead to
If successful, HIFU could offer a non-surgical option to shrink breast fibroadenomas, reducing pain and anxiety.
What could go wrong
This is a completed early-stage study without a control group, so results may not confirm effectiveness. The procedure may not work for all fibroadenoma types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

113 people

The number who actually took part.

Started

Jan 2017

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female patients 18 years or older diagnosed with breast fibroadenoma and presenting at least one fibroadenoma. 2. Diagnosis of fibroadenoma must be based on: 1. Clinical examination 2. Ultrasound image alone for patients under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. The BI-RADS score of this mammogram must be 2 or 3. BI-RADS score of 4 is eligible if biopsy indicates fibroadenoma with concordance. 3. Histologic confirmation by core needle biopsy. 3. Patient is a candidate for the surgery. 4. The fibroadenoma treatment volume must be at least 5 mm and no more than 26 mm from the skin. This criterion should be evaluated immediately prior treatment, once the breast is immobilized and potentially compressed. 5. The rib cage should not be in the prefocal ultrasound path or behind the target fibroadenoma (minimum distance from the posterior wall of the fibroadenoma must be at least 10 mm). This criterion shall be evaluated immediately prior to treatment, once breast is immobilized and potentially compressed. 6. The fibroadenoma is 1 cm or greater at its largest dimension and no less than 7.5 mm in the anterior-posterior dimension (measured by ultrasound). Focal point for HIFU treatment must also be at least 3 mm from any border of the fibroadenoma. 7. Patient's fibroadenoma size is greater or equal to 0.2 cc and less than 10 cc in volume (measured by ultrasound on the day of the procedure). 8. Fibroadenoma is palpable. 9. Pain ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days 10. Anxiety ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days 11. Patient has signed a written informed consent. Exclusion Criteria: 1. Patient is pregnant or nursing. 2. Presence of calcified fibroadenoma. Calcification will be determined with mammography. In women \> 35 years old, the diagnostic mammogram should be evaluated for calcification. In women ≤ 35 years old, a single view mammogram of the affected breast is sufficient for evaluation of calcification. Women ≤ 35 years old will be excluded based on the findings of calcification on a single view mammogram. 3. Patient with history of breast cancer or history of laser or radiation therapy to the target breast. 4. Patient with breast implants in the target breast. 5. Patient with a breast cyst within the fibroadenoma to be treated. 6. Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit. 7. Patient participating in another clinical trial involving an investigational drug, device or biologic.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast fibroadenoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bellevue Hospital Center

    New York, New York, 10016, United States

  • Montefiore-Einstein Center for Cancer Care

    New York, New York, United States

  • New York Columbia University Medical Center

    New York, New York, 10032, United States

  • University of Virginia Health system

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.